[PDF][PDF] 新冠肺炎COVID-19 藥物發展
田至峰， 蔡宛庭， 蔡瑋祥， 余冠儀 - 感染控制雜誌, 2023 - cdc.gov.tw
… ,molnupiravir 施受者體內清除 病毒RNA 量所需時間與placebo 對 照組相比明顯降低[4].Molnupiravir
雖… with coronavirus disease 2019 (COVID-19): a comparative analysis of in-hospital all-…
雖… with coronavirus disease 2019 (COVID-19): a comparative analysis of in-hospital all-…
Acupoint stimulation for long COVID: A promising intervention: 穴位刺激治疗长新冠: 一种有前景的干预措施
BW Feng, PJ Rong - World Journal of Acupuncture-Moxibustion, 2023 - Elsevier
… been approved for use in acute COVID-19; however, Pfizer has … Several antiviral drugs,
such as remdesivir, molnupiravir, … hospitalized patients during the early phase of the COVID-19 …
such as remdesivir, molnupiravir, … hospitalized patients during the early phase of the COVID-19 …
[HTML][HTML] Acupoint stimulation for long COVID: A promising intervention: 穴位刺激治疗长新冠: 一种有前景的干预措施
BW Feng, PJ Rong - World Journal of Acupuncture-Moxibustion - ncbi.nlm.nih.gov
… been approved for use in acute COVID-19; however, Pfizer has … Several antiviral drugs,
such as remdesivir, molnupiravir, … hospitalized patients during the early phase of the COVID-19 …
such as remdesivir, molnupiravir, … hospitalized patients during the early phase of the COVID-19 …
[PDF][PDF] 新型冠状病毒感染预防药物研究进展
李奇隆， 钟武， 朱贺， 樊士勇 - 临床药物治疗杂志, 2023 - lcywzlzz.com
… of prophylaxis drugs for COVID-19,including antibody drugs … 韦(molnupiravir),ensitrelvir,分别
获批用于 住院COVID-19患者,… of patients hospitalised with COVID-19:a randomised,double-…
获批用于 住院COVID-19患者,… of patients hospitalised with COVID-19:a randomised,double-…
[PDF][PDF] 新型冠状病毒肺炎的抗病毒治疗进展
石浩川， 潘蕾 - 中国现代医药杂志, 2024 - zgxdyyzz.com.cn
… 非住院COVID-19 成年患者,试验 最终表明:对于有症状的COVID-19 非… of ribavirin in adults
hospitalized with severe COVID-19[J].J … Molnupiravir plus usual care versus usual care alone as …
hospitalized with severe COVID-19[J].J … Molnupiravir plus usual care versus usual care alone as …
[PDF][PDF] 2022 年全球新冠肺炎疫苗和药物研究热点回眸
刘丽丽， 黄瑶庆， 高月红， 陆彩女， 王春丽， 毛艳艳 - 科技导报, 2023 - kjdb.org
… COVID-19: Molnupiravir reduces risk of hos⁃ pital admission or death by 50% in … the rate
of hospitalization for COVID-19 male outpatients: A Randomized double-blinded placebo-con⁃ …
of hospitalization for COVID-19 male outpatients: A Randomized double-blinded placebo-con⁃ …
[PDF][PDF] 氨咖黄敏胶囊治疗轻型新型冠状病毒肺炎的临床观察
牛常明， 贾凌， 哈维超， 张国强， 高天明， 葛鑫… - 中国抗生素杂志, 2022 - zgkss.com.cn
… investigational oral antiviral molnupiravir reduced the risk of hospitalization or death by …
placebo for patients with mild or moderate COVID-19 in positive interim analysis of phase 3 study[…
placebo for patients with mild or moderate COVID-19 in positive interim analysis of phase 3 study[…
[HTML][HTML] 2021 年新冠病毒变异, 跨种传播及疫苗和药物研究热点回眸
杨婧， 荣文婉， 桓瑜， 龚玉环， 毕玉海 - 科技导报, 2022 - kjdb.org
… Modeling of future COVID-19 cases, hospitalizations, and deaths, by vaccination rates
and … status at 11 days in patients with moderate COVID-19:A randomized clinical trial[J].The …
and … status at 11 days in patients with moderate COVID-19:A randomized clinical trial[J].The …